LUC7 Antibody

What is LUC7 and what are its primary functions in cellular processes?

LUC7 proteins function as critical regulators of pre-mRNA splicing, specifically through their interaction with the U1 snRNP complex at 5′ splice sites (5′SS). These proteins broadly regulate mRNA splicing in both human cells and other organisms. Recent research has revealed that LUC7 family members differentially regulate two major classes of 5′ splice sites, thereby influencing exon inclusion or skipping across thousands of genes . Structurally, LUC7 proteins possess N-terminal zinc finger domains that interact with the U1:5′SS duplex, directly affecting splice site recognition and contributing to splicing regulation . This RNA processing role makes LUC7 proteins particularly important in cellular differentiation and metabolism, with mutations in certain family members like LUC7L2 being associated with myeloid neoplasms and other diseases .

What are the different members of the LUC7 protein family and how do they functionally differ?

The human LUC7 family consists of three paralogs with distinct functional properties:

• LUC7L2 and LUC7L: These closely related paralogs enhance splicing of "right-handed" 5′ splice sites (RH 5′SS), which have stronger consensus matching on the intron side of the near-invariant GT dinucleotide . They share similar sequence characteristics, particularly in their zinc finger domains.

• LUC7L3: This paralog enhances splicing of "left-handed" 5′ splice sites (LH 5′SS), which have stronger consensus matching upstream of the GT dinucleotide . LUC7L3 has a divergent second zinc finger domain compared to the other paralogs.

These functional differences are evolutionarily conserved, as similar patterns have been observed in plant orthologs, with Arabidopsis thaliana possessing LUC7A and LUC7B (similar to LUC7L2/LUC7L) and LUC7RL (similar to LUC7L3) . The divergence between these subfamilies occurred before the split between animals and plants, highlighting their fundamental importance in mRNA processing .

What are the key characteristics of available LUC7L antibodies for research applications?

Commercial LUC7L antibodies typically demonstrate these key characteristics:

When selecting an antibody, researchers should consider these properties in relation to their specific experimental requirements, especially when attempting to distinguish between the three LUC7 paralogs, which share sequence similarity in certain regions .

What are the optimal experimental conditions for using LUC7 antibodies in different applications?

LUC7 antibodies can be used in multiple applications with the following optimized conditions:

• Western Blotting (WB): Use at 1/1000 dilution. For optimal results, include a positive control such as human cell lysates known to express LUC7L. Expected molecular weight is approximately 43.7 kDa .

• Immunohistochemistry (IHC-P): Use at 1/50 - 1/100 dilution on paraffin-embedded sections. Antigen retrieval is typically required for optimal staining. Not tested in frozen sections (IHC-F) .

• Flow Cytometry (FCM): Use at 1/10 - 1/50 dilution. For intracellular staining, permeabilization steps are essential for antibody access .

• ELISA: Dilutions should be optimized based on the specific protocol and detection system employed .

For all applications, researchers should validate antibody specificity using appropriate controls, including lysates from cells with LUC7L knockdown/knockout or overexpression systems .

How should researchers properly store and handle LUC7 antibodies to maintain optimal activity?

To maintain antibody activity and prevent degradation, follow these storage and handling guidelines:

• Storage temperature: Aliquot and store at -20°C for long-term preservation of activity .

• Freeze/thaw cycles: Minimize repeated freeze/thaw cycles which can cause protein denaturation and loss of antibody activity. Make small working aliquots upon receipt .

• Working solutions: When preparing working solutions, use sterile techniques and keep on ice during experimental procedures.

• Buffer composition: LUC7L antibodies are typically supplied in PBS containing 0.09% sodium azide as a preservative . Be aware that sodium azide can inhibit peroxidase activity in some detection systems.

• Expiration considerations: Even with proper storage, antibody activity may diminish over extended periods, so validation before critical experiments is recommended.

Proper handling ensures reproducible results across experiments and maximizes the useful lifespan of the antibody reagent.

How can LUC7 antibodies be used to investigate differential regulation of splice sites?

Researchers can leverage LUC7 antibodies to study splice site regulation through several advanced approaches:

• Chromatin Immunoprecipitation followed by sequencing (ChIP-seq): This approach can identify genome-wide binding patterns of LUC7 proteins, particularly at 5′ splice sites with different "handedness" characteristics. Correlation between binding patterns and the "LUC7 Score" or "5′SS Balance" can reveal sequence-specific recruitment mechanisms .

• RNA Immunoprecipitation (RIP): LUC7 antibodies can be used to isolate ribonucleoprotein complexes containing LUC7 proteins, allowing identification of directly bound RNA targets and analysis of their splice site features .

• Immunofluorescence with RNA-FISH: Combined detection of LUC7 proteins and specific RNA transcripts can provide spatial information about where particular splicing events occur within the cell.

• Proximity ligation assays: These can detect interactions between LUC7 proteins and other splicing factors, revealing how different LUC7 paralogs recruit distinct splicing machinery to different classes of 5′ splice sites .

The differential regulation of "left-handed" versus "right-handed" 5′ splice sites by different LUC7 paralogs provides an excellent experimental framework for investigating sequence-specific splicing regulation .

What considerations are important when studying LUC7 proteins in disease models, particularly myeloid neoplasms?

When investigating LUC7 proteins in disease contexts, particularly in relation to myeloid neoplasms associated with LUC7L2 deletions or mutations, researchers should consider:

• Copy number variation analysis: LUC7L2 copy number alterations occur in leukemias and other myeloid neoplasms. Antibody-based techniques can help validate genomic findings at the protein level .

• Splicing pattern changes: Ablation of LUC7L2 affects splicing of exons with right-handed 5′ splice sites. RNA-seq analysis combined with immunoblotting can establish correlations between LUC7L2 protein levels and specific splicing events .

• Metabolic impacts: LUC7L2 knockout promotes an oxidative phosphorylation metabolic state, which should be evaluated alongside splicing changes to understand disease mechanisms fully .

• Differentiation effects: In iPSC-derived hematopoietic stem cells, low expression and/or loss of LUC7L2 impacts cellular differentiation, suggesting a role in developmental processes relevant to leukemogenesis .

• Compensatory mechanisms: Analysis should include evaluation of other LUC7 family members (LUC7L and LUC7L3) which may partially compensate for LUC7L2 loss, but with distinct splice site preferences .

Combining antibody-based protein detection with functional genomics approaches can provide comprehensive insights into how LUC7 dysregulation contributes to disease pathogenesis.

What are common challenges when using LUC7 antibodies and how can they be addressed?

Several challenges may arise when working with LUC7 antibodies, each with specific troubleshooting approaches:

• Cross-reactivity between paralogs: LUC7L, LUC7L2, and LUC7L3 share sequence similarity, potentially leading to cross-reactivity. Validate antibody specificity using:

  • Lysates from cells with knockout or knockdown of specific paralogs

  • Recombinant proteins as positive controls

  • Peptide competition assays to confirm epitope specificity

• Background in immunohistochemistry: High background may occur due to:

  • Insufficient blocking: Extend blocking time or try alternative blocking reagents

  • Antibody concentration: Optimize dilution range beyond recommended 1/50-1/100

  • Secondary antibody cross-reactivity: Use species-specific secondary antibodies

• Multiple bands in Western blot: This could represent:

  • Alternative splice isoforms: Verify against transcript data

  • Post-translational modifications: Consider phosphatase treatment

  • Degradation products: Use fresh samples and add protease inhibitors

• Variability in flow cytometry: Improve consistency by:

  • Standardizing permeabilization conditions

  • Using recommended dilutions (1/10-1/50)

  • Implementing consistent gating strategies

Documentation of optimization steps and inclusion of appropriate controls are essential for troubleshooting and achieving reproducible results.

How can researchers validate the specificity of LUC7 antibodies for distinguishing between different LUC7 paralogs?

Validating specificity for individual LUC7 paralogs requires systematic approaches:

• Expression systems verification:

  • Overexpress individual LUC7 paralogs (LUC7L, LUC7L2, LUC7L3) with epitope tags

  • Compare detection patterns between tag-specific antibodies and LUC7 antibodies

  • Assess cross-reactivity by immunoblotting all three paralogs with each antibody

• Genetic validation:

  • Use CRISPR/Cas9 to generate knockout cell lines for each paralog

  • Confirm absence of signal in the appropriate knockout line

  • Check for compensatory expression changes in other paralogs

• Mass spectrometry correlation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm the identity of precipitated proteins

  • Quantify relative abundance of specific peptides unique to each paralog

• Peptide mapping:

  • Design peptide competition assays using unique sequences from each paralog

  • Test whether specific peptides block antibody binding

  • Map the exact epitope recognized by each antibody

Thorough validation ensures that experimental observations can be confidently attributed to the specific LUC7 paralog being studied.

How should researchers interpret differences in LUC7 protein expression patterns in relation to splicing regulation?

When analyzing LUC7 expression data, researchers should consider the following interpretive frameworks:

• Paralog-specific effects: Changes in the relative expression of LUC7L2/LUC7L versus LUC7L3 may shift the balance between right-handed and left-handed 5′ splice site recognition. This balance should be correlated with exon inclusion/skipping patterns in alternatively spliced transcripts .

• Quantitative thresholds: Research indicates that even modest changes in LUC7 protein levels can significantly impact splicing patterns. Establish quantitative relationships between protein expression and splicing outcomes using dose-response experiments .

• Tissue-specific contexts: The same expression pattern may have different consequences in different cell types due to the presence of tissue-specific splicing factors that cooperate with LUC7 proteins.

• Evolutionary conservation: Compare expression patterns and splicing outcomes across species, particularly between plants and animals, where similar functional divisions between LUC7 paralogs have been observed .

• Clinical correlations: In disease contexts such as myeloid neoplasms, correlate LUC7L2 expression levels with specific splicing events that may contribute to pathogenesis .

The "LUC7 Score" developed from research data provides a mathematical framework for predicting which exons will be most affected by changes in specific LUC7 paralog expression .

What mathematical models and computational approaches are available for analyzing LUC7-dependent splicing patterns?

Several computational frameworks can assist in analyzing LUC7-dependent splicing:

• 5′SS Balance score: This metric quantifies the relative strength of sequence matches between the 5′ splice site and the consensus sequence on either side of the invariant GU dinucleotide. It strongly predicts sensitivity to LUC7 paralogs, with positive values indicating right-handed sites (LUC7L2/LUC7L-dependent) and negative values indicating left-handed sites (LUC7L3-dependent) .

• LUC7 Score: This refined score, derived from position weight matrices (PWMs) of LUC7L2-promoted/LUC7L3-repressed right-handed motifs versus LUC7L3-promoted/LUC7L2-repressed left-handed motifs, provides superior predictive power for splicing outcomes. The score incorporates additional sequence features beyond just consensus matching strength .

• 5′SS Enrichment analysis: This Dirichlet-multinomial model approximates the log-odds of a given 5′SS sequence occurring in significantly included or skipped exons versus unchanged exons. It can identify specific sequence motifs that are differentially regulated by each LUC7 paralog .

• Hierarchical clustering of 5′SS motifs: This approach groups 5′ splice sites based on their response patterns across multiple LUC7 perturbation experiments, revealing functionally related classes of splice sites .

These computational tools enable researchers to predict which exons will be affected by changes in LUC7 protein expression and to design targeted experiments for validating specific splicing mechanisms.